Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients

Bram Verstockt(Universitair Ziekenhuis Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Erwin Dreesen(KU Leuven), Ganel Schops(KU Leuven), Gert Van Assche(KU Leuven), An Outtier(KU Leuven), Ann Gils(KU Leuven), Maja Noman(KU Leuven), Evelien Mertens(KU Leuven), Sophie Tops(KU Leuven), Séverine Vermeire(KU Leuven)
Journal of Crohn s and Colitis
August 28, 2019
10.1093/ecco-jcc/jjz151
Cited by 38

Related Papers

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k